Treatment of Covid-19 With a Herbal Compound, Xagrotin
- Conditions
- Covid19
- Registration Number
- NCT05017493
- Lead Sponsor
- Biomad AS
- Brief Summary
This is an interventional, multi-center, randomized study. Adults with confirmed covid-19 disease not more than 10 days before enrollment date were recruited (n=361). Patients in same condition who had treated with standard of care were randomly assigned to the control group (n=178). The investigators analyzed the effect of a herbal compound, Xagrotin, and also investigated impact of different characteristics for instance gender, age, duration of disease, smoking habits and concomitant diseases on the outcome.
- Detailed Description
This is an interventional, multi-center, randomized study that has been performed in an outpatient setting (n=361). Adults with confirmed covid-19 disease not more than 10 days before enrollment date were recruited. Patients in same condition who had treated with standard of care were randomly assigned to the control group (n=178). The investigators analyzed the effect of a herbal compound, Xagrotin, and also investigated impact of different characteristics for instance gender, age, duration of disease, smoking habits and concomitant diseases on the outcome. Adverse events were registered.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 661
- Age 18 or higher
- Newly diagnosed (no longer than 10 days)
- PCR or clinically confirmed Covid-19
- Severe pulmonary disease
- Severe cardiovascular disease
- Severe hepatic disease
- Severe renal disease
- Diabetes mellitus type one
- Metabolic acidosis
- Oxygen saturation <70%
- Pregnancy
- Breast feeding
- Concomitant treatment with anticoagulation drugs
- Concomitant treatment with CYP3A4 medicines with narrow therapeutic window
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Mortality 30 days Number of Participants who died by day 30 after the enrollment
- Secondary Outcome Measures
Name Time Method Hospitalization 30 days Number of participants who have been hospitalized for Covid-19
Duration of Disease From Beginning of Treatment 30 days Number of days the patient has experienced the symptoms
Duration of Hospitalization When Occurred 30 days Days the participants were hospitalized
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Directorate of health of Sulaimani, Iraq -KRG
🇮🇶Sulaymaniyah, Iraq
Directorate of health of Sulaimani, Iraq -KRG🇮🇶Sulaymaniyah, Iraq